1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2016

Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2016" provides an overview of Obstructive Pulmonary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Obstructive Pulmonary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Obstructive Pulmonary Disease Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 1218
Abbreviations 1218
Definitions 1218
Research Methodology 1219
Secondary Research 1219
About GlobalData 1220
Contact Us 1220
Disclaimer 1220
Source 1221

List of Tables
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Region, 2016* 6
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Obstructive Pulmonary Disease Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Obstructive Pulmonary Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Obstructive Pulmonary Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Obstructive Pulmonary Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Obstructive Pulmonary Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Obstructive Pulmonary Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Obstructive Pulmonary Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Obstructive Pulmonary Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Obstructive Pulmonary Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Obstructive Pulmonary Disease to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Obstructive Pulmonary Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Obstructive Pulmonary Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Obstructive Pulmonary Disease Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Obstructive Pulmonary Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Obstructive Pulmonary Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 1219

Companies Mentioned
GlaxoSmithKline Plc
AstraZeneca Plc
C. H. Boehringer Sohn AG and Co KG
Novartis AG
Chiesi Farmaceutici SpA
Pfizer Inc
Quintiles Transnational Holdings Inc
Takeda Pharmaceutical Company Ltd
Parexel International Corp
Sumitomo Dainippon Pharma Co Ltd

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Summary Hypertension is a serious and common medical condition ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.